BC Cancer investigators participate in CCTG VISION Leadership Program

Three BC Cancer clinical investigators are participating in the Canadian Cancer Trials Group (CCTG) VISION – Investigator Leadership Training Program, a new education and mentorship initiative focused on developing leadership skills among current and emerging clinical trialists.

Drs. Leah Lambert, Jonathan Loree and Lucia Nappi are part of the inaugural VISION cohort.

BC Cancer takes national honour for excellence in isotope production, research and use

BC Cancer’s Molecular Imaging and Therapeutics Program has been recognized with the Canadian Nuclear Isotope Council (CNIC) Award for Academic Leadership — a national honour celebrating the team’s visionary leadership and impact.

At the April CNIC Annual Awards Reception at the National Arts Centre in Ottawa, Dr. François Bénard, senior executive director, Research, BC Cancer accepted the award on behalf the team, including Dr. Joseph Lau, Dr. Carlos Uribe, Dr. Arman Rahmim, Dr. Kuo-Shyan Lin, Dr. Don Wilson and many others.

New enzymatic platform harnesses DNA’s programmability towards the creation of custom radiopharmaceuticals

Researchers at BC Cancer Research Institute (BCCRI) and UBC Chemistry have created a new way to build radioactive DNA molecules that could help reimagine how radiolabeled drugs are built. Using enzymes that normally copy genetic material, scientists programmed synthetic DNA to carry cancer‑fighting isotopes in precise patterns, opening the door to developing drugs that could both image tumors and destroy them with the same molecule. 

Back to top